The Global Cell Therapy Industry Continues to Rise During the Second and Third Quarters of 2012

Overview

Journal Cell Stem Cell

Publisher Cell Press

Specialty Cell Biology

Date 2012 Dec 11

PMID 23217418

Citations 5

Authors

Chris Mason

Mark J McCall

Emily J Culme-Seymour

Shalini Suthasan

Simon Edwards-Parton

Gregory A Bonfiglio

Brock C Reeve

Affiliations

Soon will be listed here.

Abstract

During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.

Citing Articles

China's Stem Cell Research and Knowledge Levels of Medical Practitioners and Students.

Luo D, Xu Z, Wang Z, Ran W Stem Cells Int. 2021; 2021:6667743.

PMID: 34113385 PMC: 8154300. DOI: 10.1155/2021/6667743.

The Progression of Regenerative Medicine and its Impact on Therapy Translation.

Jacques E, Suuronen E Clin Transl Sci. 2020; 13(3):440-450.

PMID: 31981408 PMC: 7214652. DOI: 10.1111/cts.12736.

Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials.

Kleiderman E, Boily A, Hasilo C, Knoppers B Stem Cell Res Ther. 2018; 9(1):307.

PMID: 30409192 PMC: 6225696. DOI: 10.1186/s13287-018-1055-2.

Theoretical and Practical Issues That Are Relevant When Scaling Up hMSC Microcarrier Production Processes.

Jossen V, Schirmer C, Sindi D, Eibl R, Kraume M, Portner R Stem Cells Int. 2016; 2016:4760414.

PMID: 26981131 PMC: 4766353. DOI: 10.1155/2016/4760414.

Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.

Idrus R, Abas A, Ab Rahim F, Saim A Tissue Eng Part A. 2015; 21(23-24):2812-6.

PMID: 26192075 PMC: 4684660. DOI: 10.1089/ten.TEA.2014.0521.